Skip to Content

Generic Namenda Availability

See also: Generic Namenda XR

Namenda is a brand name of memantine, approved by the FDA in the following formulation(s):

NAMENDA (memantine hydrochloride - solution;oral)

  • Manufacturer: FOREST LABS LLC
    Approval date: April 18, 2005
    Strength(s): 2MG/ML [RLD]

NAMENDA (memantine hydrochloride - tablet;oral)

  • Manufacturer: FOREST LABS LLC
    Approval date: October 16, 2003
    Strength(s): 5MG [AB], 10MG [RLD] [AB]

Has a generic version of Namenda been approved?

A generic version of Namenda has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Namenda and have been approved by the FDA:

MEMANTINE (memantine hydrochloride tablet;oral)

  • Manufacturer: SUN PHARMA GLOBAL
    Approval date: May 5, 2010
    Strength(s): 5MG [AB], 10MG [AB]

memantine hydrochloride tablet;oral

  • Manufacturer: AMNEAL PHARMS
    Approval date: April 10, 2015
    Strength(s): 5MG [AB], 10MG [AB]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: April 14, 2010
    Strength(s): 5MG [AB], 10MG [AB]
  • Manufacturer: LUPIN LTD
    Approval date: April 10, 2015
    Strength(s): 5MG [AB], 10MG [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: January 30, 2015
    Strength(s): 5MG [AB], 10MG [AB]
  • Manufacturer: TEVA PHARMS
    Approval date: October 25, 2011
    Strength(s): 5MG [AB], 10MG [AB]

Note: No generic formulation of the following product is available.

  • memantine hydrochloride - solution;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Namenda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Adamantane derivatives in the prevention and treatment of cerebral ischemia
    Patent 5,061,703
    Issued: October 29, 1991
    Inventor(s): Bormann; Joachim & Gold; Markus R. & Schatton; Wolfgang
    Assignee(s): Merz + Co. GmbH & Co.
    A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed.
    Patent expiration dates:
    • April 11, 2015
    • October 11, 2015
      Pediatric exclusivity


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.